company background image
0A4W logo

ACADIA Pharmaceuticals LSE:0A4W Stock Report

Last Price

US$16.36

Market Cap

US$2.7b

7D

-0.7%

1Y

-26.3%

Updated

23 Nov, 2024

Data

Company Financials +

ACADIA Pharmaceuticals Inc.

LSE:0A4W Stock Report

Market Cap: US$2.7b

0A4W Stock Overview

A biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. More details

0A4W fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance4/6
Financial Health6/6
Dividends0/6

ACADIA Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ACADIA Pharmaceuticals
Historical stock prices
Current Share PriceUS$16.36
52 Week HighUS$32.51
52 Week LowUS$14.18
Beta0.38
11 Month Change13.23%
3 Month Change3.43%
1 Year Change-26.33%
33 Year Change-12.56%
5 Year Changen/a
Change since IPO-61.13%

Recent News & Updates

Recent updates

Shareholder Returns

0A4WGB BiotechsGB Market
7D-0.7%0.3%2.2%
1Y-26.3%-18.3%8.0%

Return vs Industry: 0A4W underperformed the UK Biotechs industry which returned -18.3% over the past year.

Return vs Market: 0A4W underperformed the UK Market which returned 8% over the past year.

Price Volatility

Is 0A4W's price volatile compared to industry and market?
0A4W volatility
0A4W Average Weekly Movement5.7%
Biotechs Industry Average Movement9.6%
Market Average Movement4.8%
10% most volatile stocks in GB Market10.3%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0A4W has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0A4W's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1993620Catherine Owen Adamswww.acadia.com

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer’s disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms.

ACADIA Pharmaceuticals Inc. Fundamentals Summary

How do ACADIA Pharmaceuticals's earnings and revenue compare to its market cap?
0A4W fundamental statistics
Market capUS$2.72b
Earnings (TTM)US$128.51m
Revenue (TTM)US$929.24m

21.2x

P/E Ratio

2.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0A4W income statement (TTM)
RevenueUS$929.24m
Cost of RevenueUS$347.19m
Gross ProfitUS$582.05m
Other ExpensesUS$453.54m
EarningsUS$128.51m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.77
Gross Margin62.64%
Net Profit Margin13.83%
Debt/Equity Ratio0%

How did 0A4W perform over the long term?

See historical performance and comparison